Conferences - Results from #580

ASTRO 2024: MRI-Guided versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial October 2, 2024

ASTRO 2024: Dose Escalated Pelvic Lymph Node IMRT with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prospective Trial October 2, 2024

ASTRO 2024: Emerging Systemic Therapy and Trials for Small Cell Cancer of the Genitourinary Tract October 1, 2024

ASTRO 2024: The RAVENS Phase 2 Randomized Trial: Outcomes of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS October 1, 2024

ASTRO 2024: Role of Surgery in the Management of Genitourinary Small Cell Tumors October 1, 2024

ASTRO 2024: Radiation Therapy for Small Cell Neuroendocrine Tumors of the Genitourinary Tract October 1, 2024

ASTRO 2024: Radiation Therapy for Small Cell Bladder Cancers October 1, 2024

ASTRO 2024: Pathologic Features of Small Cell Variants of the Genitourinary Tract October 1, 2024

ASTRO 2024: Combination of Nivolumab Immunotherapy with Radiation Therapy and Androgen Deprivation Therapy in the Management of Gleason Group 5 Prostate Cancer: Final Analysis of a Phase 2 Trial October 1, 2024

ASTRO 2024: Hypofractionated, Dose-Escalated Radiation vs. Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase 3, Prospective, Randomized Controlled Trial October 1, 2024

ASTRO 2024: Pembrolizumab Monotherapy Following Tri-Modality Treatment for Selected Patients with Muscle-Invasive Bladder Cancer October 1, 2024

ASTRO 2024: Bi-Institutional Safety Analysis of Combining Radiotherapy and Enfortumab Vedotin in Advanced Urothelial Cancer September 30, 2024

ASTRO 2024: Natural History after Likely Cure versus Recurrence after ProsTate RadiOtheRapy (RAPTOR): A Pooled Analysis of More than 13000 Patients from 21 Randomized Controlled Trials September 30, 2024

ASTRO 2024: Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Localized Prostate Cancer September 30, 2024

ASTRO 2024: Role of Brachytherapy for Unfavorable Intermediate Risk Prostate Cancer September 30, 2024

ASTRO 2024: Long-Term Patient-reported Health-Related Quality of Life in the Randomized FORMULA-509 Trial September 30, 2024

ASTRO 2024: Prospective Evaluation of Supplemental External Beam Radiotherapy in Higher Risk Prostate Cancer Patients Implanted with Pd-103: Long-Term Results of the 44/20/0 Trials September 30, 2024

ASTRO 2024: Randomized Controlled Trial of PSMA-PET Image Guided Intensification of Salvage Radiotherapy after Radical Prostatectomy: Which Patients Are Most Likely to Benefit and Other Secondary Analyses September 30, 2024

ASTRO 2024: Quality of Life in Patients Enrolled in a Randomized Clinical Trial Evaluating Hypofractionated Radiotherapy for Intermediate Risk Prostate Cancer September 30, 2024

ASTRO 2024: A Randomized Comparison of Low Dose Rate or High Dose Rate Brachytherapy Combined with External Beam Radiation for Unfavorable Intermediate or High-risk Prostate Cancer: Efficacy Results at Median 6 Years September 30, 2024

Page 30 of 616